- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05363189
Optimizing Postoperative Recovery After Breast Reconstruction With Autologous Tissue (BestDIEP) (BestDIEP)
August 7, 2023 updated by: Vastra Gotaland Region
Women who have their breast reconstructed with autologous tissue seem to be more satisfied with their breast.
However, autologous breast reconstruction entails a bigger operation, and the usage of more health care resources, than some other methods, such as implant-based techniques.
The main objectives of the present study are to investigate if pre- peri- and postoperative protocols can be safely modified, so the operation demands less resources, while maintaining a low complication rate and a high patient satisfaction.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
380
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emma Hansson, MD, PhD
- Phone Number: 0046313421000
- Email: emma.em.hansson@vgregion.se
Study Locations
-
-
-
Gothenburg, Sweden, 413 45
- Recruiting
- Sahlgrenska University Hospital
-
Contact:
- Emma Hansson, PhD
- Phone Number: +46 31 342 10 00
- Email: emma.hansson.2@gu.se
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Biological women undergoing breast reconstruction with a deep inferior epigastric artery perforator flap in Sahlgrenska university hospital.
Description
Inclusion Criteria:
- Operated or will be operated with a DIEP flap in the department
- >18 years of age
Exclusion Criteria:
- Inability to leave informed consent
- Inability to understand and speak Swedish (for the questionnaire)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
No venons augmentation
Retrospective group of patients who have not received venous augmentation during their operation.
|
Traditional deep inferior epigastric artery perforator flap (DIEP)
|
Venous augmentation
Retrospective group of patients who have received venous augmentation during their operation.
|
Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
Other Names:
|
ERAS protocol
Retrospective group operated according to the traditional ERAS (enhanced recovery after surgery) protocol
|
Pre-, peri-, and post-operative care as described in the ERAS protocol
|
Sahlgrenska recovery protocol
Prospective group operated according to the Sahlgrenska recovery protocol.
|
Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Re-operations
Time Frame: 7 days
|
Any re-operations performed for any cause during the first 7 days after the operation
|
7 days
|
Length of stay (LOS) in hospital
Time Frame: 7 days
|
Number of days the patient stays in the hospital after the operation
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported satisfaction and quality of life
Time Frame: 12 months
|
Measured with BREAST-Q reconstruction.
The patient scores different items om a scale and a sum score of 0-100 is calculated for each domain.
A higher score indicates a higher satisfaction/quality of life.
|
12 months
|
Surgical corrections
Time Frame: 5 years
|
Number of cosmetic corrections.
All types of corrections performed in general or local anesthetics will be included.
|
5 years
|
Costs
Time Frame: 5 years
|
Health economical analysis of direct and indirect cost related to the different protocols
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 2, 2022
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
May 2, 2022
First Submitted That Met QC Criteria
May 2, 2022
First Posted (Actual)
May 5, 2022
Study Record Updates
Last Update Posted (Actual)
August 8, 2023
Last Update Submitted That Met QC Criteria
August 7, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 2022-01423-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on No venous augmentation
-
McGill UniversityCanadian Institutes of Health Research (CIHR); Centre for Interdisciplinary... and other collaboratorsNot yet recruitingCognitive Impairment | Stroke, Ischemic | Stroke Hemorrhagic
-
Queen Mary University of LondonGeistlich Pharma AGRecruitingTooth Loss | Wound Heal | Dental DiseasesUnited Kingdom
-
Shirley Ryan AbilityLabU.S. Department of EducationCompleted
-
University of IowaEnrolling by invitationTooth Extraction | Immediate Implant PlacementUnited States
-
Universidad Científica del SurNYU Langone HealthCompletedDental Implants | Bone Regeneration | Cone-beam Computed Tomography | Bone Substitutes | Bone TransplantationPeru
-
University of BernSonnenhof Hospital, BernTerminatedOsteoporosis | Vertebral FractureSwitzerland
-
University Hospital of FerraraUniversity of Modena and Reggio EmiliaCompleted
-
The Catholic University of KoreaUnknown
-
Universidad Complutense de MadridOsteology FoundationRecruitingDental Malocclusion | Maxillary DeficiencySpain
-
DFINE Inc.WithdrawnMultiple Myeloma | Compression Fracture of Vertebral Column